Which baseline laboratory tests should I obtain for a patient with chronic kidney disease stage IIIb (eGFR 30–44 mL/min/1.73 m²) before referring to a nephrologist?

Laboratory Workup Before Nephrology Referral for CKD Stage IIIb

Before referring a CKD stage IIIb patient to nephrology, obtain a comprehensive metabolic panel, complete blood count, intact parathyroid hormone, calcium, phosphate, 25-hydroxyvitamin D, lipid panel, hemoglobin A1c (if diabetic), and a spot urine albumin-to-creatinine ratio with urinalysis and microscopy. 1

Core Kidney Function Assessment

• Measure serum creatinine with calculated eGFR to confirm CKD stage IIIb (eGFR 30–44 mL/min/1.73 m²) and establish baseline renal function before referral. 1

• Obtain a spot urine albumin-to-creatinine ratio (UACR) to quantify proteinuria; confirm persistent albuminuria when at least two of three specimens collected over 3–6 months are abnormal. 1

• Perform urinalysis with microscopy to detect hematuria, pyuria, red cell casts, or crystals that may indicate glomerular disease or other primary renal pathology requiring urgent nephrology evaluation. 1

Metabolic Panel and Electrolytes

• Order a comprehensive metabolic panel including blood urea nitrogen, sodium, potassium, chloride, bicarbonate, glucose, calcium, and liver function tests to establish baseline metabolic status. 1

• Check serum bicarbonate to identify metabolic acidosis, which should be measured at least every 3 months in stage 3b CKD and corrected to maintain bicarbonate ≥22 mmol/L. 2

Mineral-Bone Disorder Evaluation

• Measure intact parathyroid hormone (iPTH), serum calcium, phosphate, and 25-hydroxyvitamin D at least once when eGFR falls below 45 mL/min/1.73 m², because PTH elevation typically begins when GFR drops below 60 mL/min/1.73 m². 2, 3

• Monitor calcium and phosphate every 3 months in stage 3b CKD; if either is abnormal, iPTH should be monitored every 3 months. 2

• These mineral-bone parameters are critical because hyperparathyroidism prevalence increases from 17% at eGFR 60–90 to 85% at eGFR <20 mL/min/1.73 m², making early detection essential. 4

Anemia Screening

• Obtain a complete blood count (CBC) to screen for anemia, which becomes markedly more prevalent in stage 3b CKD. 1, 3

• Hemoglobin should be checked at least every 3 months in patients with eGFR ≤30 mL/min/1.73 m². 3

• When hemoglobin falls below 12 g/dL in women or 13 g/dL in men, obtain a complete iron panel including serum iron, total iron-binding capacity, ferritin, and transferrin saturation. 3, 2

• Anemia prevalence increases from 8% at eGFR 60–90 to 41% at eGFR <20 mL/min/1.73 m², with onset typically occurring when eGFR falls below 44 mL/min/1.73 m². 4

Nutritional Status Assessment

• Measure serum albumin as part of the nutritional status evaluation; albumin should be monitored every 3 months in stage 3b CKD. 3, 2

• Unintentional weight loss >5% of body weight or serum albumin decline >0.3 g/dL or <4.0 g/dL (Bromo-Cresol-Green assay) indicates malnutrition requiring dietary counseling. 3

Cardiovascular Risk Assessment

• Obtain a fasting lipid panel including total cholesterol, LDL, HDL, and triglycerides, because dyslipidemia is common in CKD and heightens cardiovascular risk. 3, 2

• Measure hemoglobin A1c in diabetic patients to assess glycemic control, as optimization of diabetes management is critical in CKD progression. 1

Additional Considerations

• Do not obtain bone scans or brain imaging unless the patient presents with specific symptoms such as bone pain, markedly elevated alkaline phosphatase, or neurological signs. 1

• Do not rely solely on dipstick protein testing; quantitative urine albumin measurement is required for accurate staging and risk stratification. 1

• Lactate dehydrogenase (LDH) may be included at the physician's discretion when additional enzymatic information may be clinically useful. 1

Common Pitfalls to Avoid

• Do not use serum creatinine alone; always calculate eGFR using a validated equation (CKD-EPI 2021) and confirm chronicity with repeat testing over ≥3 months. 2, 5

• Do not omit albuminuria testing; eGFR and UACR provide independent prognostic information for cardiovascular events, CKD progression, and mortality. 2

• Recognize that metabolic complications manifest earlier than the eGFR alone suggests—patients who progress from stage 3b to stage 4 show significantly lower hemoglobin, bicarbonate, calcium, and albumin values even when initial eGFR values are equivalent to non-progressors. 6

• The GFR threshold for detecting complications with 90% sensitivity is 50 mL/min/1.73 m² for hyperparathyroidism and 44 mL/min/1.73 m² for anemia, meaning these complications are already emerging in stage 3b CKD. 4